Moderna, Inc. Furnishes Financial Results and Business Updates
Summary
Moderna, Inc. (NASDAQ:MRNA) furnished its second quarter 2026 financial results and business updates on July 31, 2026, via Ex. 99.1 press release. The company reported revenue of $0.1 billion, a GAAP net loss of $(0.8) billion, and GAAP EPS of $(1.97). Moderna reiterated its plan for up to 10% revenue growth in 2026. * Improved 2026 GAAP operating expense outlook by approximately $0.2 billion. * Expected 2026 year-end cash balance of $4.7 - 5.2 billion. * Anticipates potential approval of mFLUSIVA (seasonal influenza vaccine) by August 5th PDUFA date. * mRNA-1403 (norovirus vaccine) did not meet statistical criteria for early success at Phase 3 interim analysis; additional cohort to be enrolled.
Why It Matters
This update provides key Q2 2026 financial performance, including revenue, net loss, and EPS. Investors should note the improved 2026 GAAP operating expense outlook and updated year-end cash balance (via Ex. 99.1), alongside critical pipeline developments for mFLUSIVA and mRNA-1403, which significantly impact future growth prospects and market position.
These filing summaries are free and always will be. If this helped you spot material events, consider supporting us.
Want to see how MRNA traded around this filing?
Check real-time charts and technical analysis on TradingView to see market reaction to this event.
View MRNA Charts on TradingViewAffiliate link
Is this filing part of a pattern?
One disclosure is noise. Get a structured briefing covering 12 months of SEC filings, disclosure signals, and what to watch next.
Filing Details
Reported Items
Additional Information
- CIK Number
- 0001682852
- Filing Date
- Friday, July 31, 2026
- Filing Time
- 12:00 AM UTC
- Form Type
- 8-K
- Materiality Level
- high
- Sentiment
- positive